Drug repurposing to enhance antitumor response to pd-1/pd-l1 immune checkpoint inhibitors

HIGHLIGHTS

• who: Xavier Thuru et al. from the University of Lille, CNRS, Inserm, CHU Lille, UMR9020-UMR1277-Canther-Cancer Heterogeneity Oncowitan, Scientific Consulting Office, Lille, France have published the Article: Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors, in the Journal: Cancers 2022, 3368 of /2022/
• what: __SECTION__ Conclusions.

SUMMARY

There is a. key crosstalk the endocrine system the immune system,modulation with important the activity of T_cells in the and the immuneand system, with important of themodulation activity of Tofcells in the presence ence of . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.